Loading
Principal investigator of FRESCO, the Chinese trial that first proved fruquintinib works in refractory colorectal cancer.
Jin Li is Professor of Medical Oncology at Fudan University Shanghai Cancer Center and Shanghai East Hospital, specialising in gastrointestinal oncology. He was principal investigator of FRESCO, the Chinese trial that first showed fruquintinib works in previously treated metastatic colorectal cancer, a result later extended internationally in FRESCO-2. He has also led other Chinese gastrointestinal oncology trials, including apatinib in gastric cancer, contributing drugs now used around the world. His publications include the FRESCO randomised trial of fruquintinib against placebo in refractory colorectal cancer.
Shares FRESCO-2, Fruquintinib, Colorectal cancer.
Shares FRESCO-2, Fruquintinib, Colorectal cancer.
Shares Chinese Society of Clinical Oncology, Fruquintinib, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
Shares FRESCO-2, Fruquintinib, Colorectal cancer.
Shares Fruquintinib, Colorectal cancer.
Shares FRESCO-2, Colorectal cancer.
Shares Fruquintinib, Gastric & gastro-oesophageal junction cancer.
Shares Fruquintinib, Colorectal cancer.